The angiotensin II receptor antagonist irbesartan for the treatment of portal hypertension: A placebo controlled, double-blind study.

被引：0
|
作者：
Schepke, M [1 ]
Werner, E [1 ]
Bieker, E [1 ]
Schiedermaier, P [1 ]
Hofer, U [1 ]
Layer, G [1 ]
Heller, J [1 ]
Neef, M [1 ]
Sauerbruch, T [1 ]
机构：
[1] Univ Bonn, D-5300 Bonn, Germany
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
985
引用
收藏
页码：406A / 406A
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension - A double-blind, placebo-controlled, dose-titration study
    Guthrie, R
    Saini, R
    Herman, T
    Pleskow, W
    Sprecher, D
    Collins, G
    CLINICAL DRUG INVESTIGATION, 1998, 15 (03) : 217 - 227
  • [2] Efficacy of Irbesartan, an angiotensin II receptor selective antagonist, in the treatment of portal hypertension
    Debernardi-Venon, W
    Barletti, C
    Marzano, A
    Alessandria, C
    Todros, L
    Saracco, G
    Repici, A
    Rocca, G
    Rizzetto, M
    HEPATOLOGY, 1999, 30 (04) : 219A - 219A
  • [3] Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary HypertensionA Double-Blind, Placebo-Controlled, Dose-Titration Study
    Robert M. Guthrie
    Ravi Saini
    Theodore Herman
    Warren Pleskow
    Dennis Sprecher
    Gregory Collins
    Clinical Drug Investigation, 1998, 15 : 217 - 227
  • [4] Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension
    Debernardi-Venon, W
    Barletti, C
    Alessandria, C
    Marzano, A
    Baronio, M
    Todros, L
    Saracco, G
    Repici, A
    Rizzetto, M
    DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (02) : 401 - 404
  • [5] Efficacy of Irbesartan, a Receptor Selective Antagonist of Angiotensin II, in Reducing Portal Hypertension
    Wilma Debernardi-Venon
    Claudio Barletti
    Carlo Alessandria
    Alfredo Marzano
    M. Baronio
    Luca Todros
    Giorgio Saracco
    Alessandro Repici
    Mario Rizzetto
    Digestive Diseases and Sciences, 2002, 47 : 401 - 404
  • [6] A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension
    Mimran, A
    Ruilope, L
    Kerwin, L
    Nys, M
    Owens, D
    Kassler-Taub, K
    Osbakken, M
    JOURNAL OF HUMAN HYPERTENSION, 1998, 12 (03) : 203 - 208
  • [7] A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension
    A Mimran
    L Ruilope
    L Kerwin
    M Nys
    D Owens
    K Kassler-Taub
    M Osbakken
    Journal of Human Hypertension, 1998, 12 : 203 - 208
  • [8] Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension
    Schepke, M
    Werner, E
    Biecker, E
    Schiedermaier, P
    Heller, J
    Neef, M
    Stoffel-Wagner, B
    Hofer, U
    Caselmann, WH
    Sauerbruch, T
    GASTROENTEROLOGY, 2001, 121 (02) : 389 - 395
  • [9] EFFICACY OF AN NMDA RECEPTOR ANTAGONIST IN THE TREATMENT OF TARDIVE DYSKINESIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Pappa, Sofia
    Tzouli, Sofia
    Mavreas, Venos
    Konitsiotis, Spyros
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S358 - S358
  • [10] A Double-Blind, Placebo-Controlled Study of the Opiate Antagonist, Naltrexone, in the Treatment of Kleptomania
    Grant, Jon E.
    Kim, Suck Won
    Odlaug, Brian L.
    BIOLOGICAL PSYCHIATRY, 2009, 65 (07) : 600 - 606
12345